Abstract: An offloading schedule for offloading image frames that are to be generated by an AR device in a subsequent time period is determined, the offloading schedule identifying certain image frames generated in the subsequent time period that are to be offloaded and certain image frames generated in the subsequent time period that are not to be offloaded, the offloading schedule being selected from a plurality of offloading schedules based on a tracking stride of the offloading schedule. The AR device sends to a computing device at least some of the image frames generated in the subsequent time period in accordance with the offloading schedule.

Abstract: The disclosure provides, inter alia, dual-layer, semi-permeable, fibrosis-resistant, hydrogel polymer enclosures, optionally containing cells, such as mammalian cells, where the enclosures are suitable for administration to a subject in need thereof and further wherein the enclosure are scalable for large volumes of delivered cells. The disclosure further provides methods of making and using the enclosures, for example, in therapeutic methods, such as treating disorders of the liver or other cells and organs treatable with, for example secretory and/or catalytic cells.

Abstract: A cloud security control platform and method enforces security controls across multiple cloud environments, services and disparate teams while providing a frictionless “Permissions on Demand” mechanism for approvals and exceptions. In contrast to the prior art, security is evaluated on a permission by permission basis, with the default being that all permissions are denied and then only given to a particular identity on an as-needed basis. This approach reduces the security risks associated with the vast capabilities available in Public Cloud environments and permits an organization that uses the platform to grant access, approve exceptions and delegate approvals with the appropriate compliance.

Abstract: The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the incubation and/or the cultivation is performed in the presence of recombinant IL-2. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.

Abstract: Video data that depicts a facial motion of a face of a particular user of a computing device is obtained. A determination is made that a network performance metric for a network connection is less than a threshold network performance metric. Responsive to the determination, motion capture information is determined based on the video data. The motion capture information is indicative of the facial motion of the face of the particular user. The motion capture information is transmitted to the computing system. The motion capture information is for animation of a photorealistic three-dimensional representation of the face of the particular user.

Abstract: Video data that depicts a face of a particular user is obtained. The video data is processed with a plurality of machine-learned models of a user-specific model ensemble for photorealistic facial representation to obtain a corresponding plurality of model outputs. The plurality of machine-learned models comprises one or more of a mesh representation model trained to generate a 3D polygonal mesh representation of the face of the particular user, a machine-learned texture representation model trained to generate a plurality of textures representative of the face of the particular user, or subsurface anatomical representation model(s) trained to generate sub-surface model outputs, each including a representation of a different sub-surface anatomy of the face of the particular user. At least one machine-learned model is optimized based on a loss function that evaluates the at least one model output.

Abstract: The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the incubation and/or the cultivation is performed in the presence of recombinant IL-2. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.

Abstract: Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.

Abstract: A cloud security control platform and method enforces security controls across multiple cloud environments, services and disparate teams while providing a frictionless “Permissions on Demand” mechanism for approvals and exceptions. In contrast to the prior art, security is evaluated on a permission by permission basis, with the default being that all permissions are denied and then only given to a particular identity on an as-needed basis. This approach reduces the security risks associated with the vast capabilities available in Public Cloud environments and permits an organization that uses the platform to grant access, approve exceptions and delegate approvals with the appropriate compliance.

Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

Abstract: Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.

Abstract: Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.

Abstract: An offloading schedule for offloading image frames that are to be generated by an AR device in a subsequent time period is determined, the offloading schedule identifying certain image frames generated in the subsequent time period that are to be offloaded and certain image frames generated in the subsequent time period that are not to be offloaded, the offloading schedule being selected from a plurality of offloading schedules based on a tracking stride of the offloading schedule. The AR device sends to a computing device at least some of the image frames generated in the subsequent time period in accordance with the offloading schedule.

Abstract: A first computing device establishes a communication session with a second computing device. The first computing device receives a first motion capture data stream originating from the second computing device during the communication session, the first motion capture data stream quantifying real-time movements of a first user of the second computing device. The first computing device renders, to a display device, imagery of an animation of a three-dimensional (3D) model of the first user based on the first motion capture data stream that depicts the real-time movements of the first user.

Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.

Abstract: Centrifugal compressors can incorporate a side stream flow of intermediate pressure vapor between stages of that compressor. The side stream flow can be controlled by a side stream injection port controlled by a capacity control valve that has a curved surface facing a flow of refrigerant from the first stage to the second stage. The capacity control valve can allow or obstruct flow through the side stream injection port. The capacity control valve can extend and retract in a direction substantially perpendicular to the direction of flow from the first stage impeller to the second stage impeller. The side stream injection port and the capacity control valve can be ring-shaped. The side stream injection port and the capacity control valve can allow at least some of the side stream to be introduced on a side of the capacity control valve opposite the curved surface.

Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.